{"id":"NCT00101686","sponsor":"Pfizer","briefTitle":"Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","officialTitle":"A Randomized, Multi-Center Phase III Trial Of Irinotecan In Combination With Three Different Methods Of Administration Of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5-FU (Day 1 & 8), And Oral Capecitabine (Day 1-14); With Celecoxib Versus Placebo As First-Line Treatment For Patients With Metastatic Colorectal Cancer Study Amended April 23, 2004 To Include Bevacizumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-02","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2005-01-13","resultsPosted":"2009-11-26","lastUpdate":"2010-01-12"},"enrollment":547,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Neoplasms"],"interventions":[{"type":"DRUG","name":"Modified Bolus 5-FU/LV with Irinotecan","otherNames":[]},{"type":"DRUG","name":"FOLFIRI + bevacizumab","otherNames":[]},{"type":"DRUG","name":"miFL + bevacizumab","otherNames":[]},{"type":"DRUG","name":"Infusional 5-FU/LV with Irinotecan","otherNames":[]},{"type":"DRUG","name":"Oral Capecitabine with Irinotecan","otherNames":[]}],"arms":[{"label":"Modified Bolus 5-FU/LV with Irinotecan","type":"EXPERIMENTAL"},{"label":"FOLFIRI + bevacizumab","type":"EXPERIMENTAL"},{"label":"miFL + bevacizumab","type":"EXPERIMENTAL"},{"label":"Infusional 5-FU/LV with Irinotecan","type":"EXPERIMENTAL"},{"label":"Oral Capecitabine with Irinotecan","type":"OTHER"}],"summary":"This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral). In the second period of study it compares FOLFIRI \\[a chemotherapy regime that combines bolus irinotecan and leucovorin \\[LV\\] with infusional 5-fluorouracil (5-FU)\\] + bevacizumab and mlFL + bevacizumab. Measures of efficacy and safety will be reported.","primaryOutcome":{"measure":"Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL","timeFrame":"every 6 weeks until disease progression","effectByArm":[{"arm":"FOLFIRI","deltaMin":8.18,"sd":null},{"arm":"mIFL","deltaMin":6.01,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0152"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":175,"countries":["United States","Australia","Canada","New Zealand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":137},"commonTop":["Diarrhoea","Nausea","Fatigue","Vomiting","Abdominal pain"]}}